Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00824291|
Recruitment Status : Completed
First Posted : January 16, 2009
Results First Posted : November 25, 2010
Last Update Posted : March 10, 2011
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Depressive Disorder, Major||Drug: desvenlafaxine succinate sustained release Genetic: Genotyping||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||437 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||October 2009|
|Actual Study Completion Date :||November 2009|
|Placebo Comparator: 1||
Drug: desvenlafaxine succinate sustained release
50 mg/day oral tablet for 12 weeks
Other Name: Pristiq
CYP2D6 genotyping at randomization
- Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12 [ Time Frame: At Baseline and Week 12. ]HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilt feelings, suicide, sleep disturbances, anxiety levels and weight loss). Total score ranges from 0 to 52; higher scores indicate more depression. Change from baseline: mean at observation minus mean at baseline.
- Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 12 [ Time Frame: At Baseline and Week 12. ]Participant rated scale was used to assess the effect of the participant's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Individual item scores range from 0 to 10.
- Clinical Global Impression Scale - Improvement (CGI- I) Score at Week 12 [ Time Frame: At Baseline and Week 12. ]CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Change = score at observation minus score at baseline.
- Clinical Global Impressions Scale - Severity of Illness (CGI-S) at Week 12 [ Time Frame: At Baseline and Week 12. ]CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline.
- Change From Baseline on Work and Activities Item of HAM-D17 at Week 12 [ Time Frame: At Baseline and Week 12. ]The Work and Activities Item of the HAM-D17 is item 7 of HAM-D17. Scoring range from 0 to 4.
- Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS) at Week 12 [ Time Frame: At Baseline and Week 12. ]Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
- Change From Baseline on Worry Anxiety Tension Scale (WATS) at Week 12 [ Time Frame: At Baseline and Week 12. ]WATS: a self-administered, 3-question rating scale assesses worry, anxiety, and tension. Each item was a visual analog scale on which the participant circles a number from 0 to 10. Higher scores indicated worse function. WATS total score was the sum of the 3 items. If 1 item was missing, the total score would be missing.
- Change From Baseline on Stress and Social Support Scales at Week 12 [ Time Frame: At Baseline and Week 12. ]Stress and Social Support Scales: self-administered rating scale where item 1 is the stress vulnerability scale measuring how much the subject was set back by stressful events on an 11-point scale ranging from 0 (not at all) to 10 (extremely) and item 2 is an 11-point scale ranging from 0 to 100 percent of the amount of support the subject received from relatives and friends.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||19 Years to 74 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Outpatient men and women, between the ages of 18 to 75 years, fluent in both written and spoken English.
- Employed for 20 hours or more for a minimum of 1 month prior to baseline.
- Primary diagnosis of Major Depressive Disorder with symptoms for at least 30 days prior to baseline.
- Treatment with desvenlafaxine succinate sustained release at any time in the past and/or venlafaxine (Effexor or Effexor XR) 1 year prior to baseline.
- Treatment-resistant defined as any of the following failed treatments in the past 3 years: 3 or more previous adequate trials of >=2 classes of antidepressant medication, electroconvulsive therapy, or psychotherapy (2 adequate trials).
- Current (within 12 months prior to the screening visit) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder.
- Clinically important abnormalities on physical examination, electrocardiogram (ECG), or laboratory evaluations.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00824291
|Study Director:||Pfizer CT.gov Call Center||Pfizer|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Director, Clinical Trial Disclosure Group, Pfizer, Inc|
|Other Study ID Numbers:||
|First Posted:||January 16, 2009 Key Record Dates|
|Results First Posted:||November 25, 2010|
|Last Update Posted:||March 10, 2011|
|Last Verified:||March 2011|
Major Depressive Disorder
Depressive Disorder, Major
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs